Vontobel Holding Ltd. Sells 11,758 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Vontobel Holding Ltd. trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 15.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 62,570 shares of the medical research company's stock after selling 11,758 shares during the period. Vontobel Holding Ltd.'s holdings in IQVIA were worth $14,827,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in IQV. Versant Capital Management Inc boosted its holdings in IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company's stock worth $26,000 after buying an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new stake in shares of IQVIA in the 2nd quarter valued at approximately $27,000. Park Place Capital Corp purchased a new stake in shares of IQVIA in the 3rd quarter valued at approximately $28,000. Itau Unibanco Holding S.A. purchased a new stake in shares of IQVIA in the 2nd quarter valued at approximately $29,000. Finally, Rise Advisors LLC purchased a new stake in shares of IQVIA in the 1st quarter valued at approximately $31,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Up 0.4 %

Shares of IQV traded up $0.83 during mid-day trading on Thursday, hitting $233.89. 908,293 shares of the company's stock were exchanged, compared to its average volume of 1,067,812. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The firm has a fifty day moving average of $239.09 and a two-hundred day moving average of $231.35. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The stock has a market cap of $42.61 billion, a price-to-earnings ratio of 31.95, a P/E/G ratio of 2.18 and a beta of 1.49.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. During the same period last year, the business posted $2.22 EPS. IQVIA's revenue was up 2.3% compared to the same quarter last year. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. StockNews.com upgraded shares of IQVIA from a "hold" rating to a "buy" rating in a research report on Monday. Redburn Atlantic assumed coverage on shares of IQVIA in a research report on Monday. They issued a "buy" rating and a $276.00 price target for the company. Jefferies Financial Group downgraded shares of IQVIA from a "buy" rating to a "hold" rating and reduced their price target for the company from $266.00 to $242.00 in a research report on Wednesday, July 24th. JPMorgan Chase & Co. increased their target price on shares of IQVIA from $260.00 to $288.00 and gave the stock an "overweight" rating in a research report on Monday, August 5th. Finally, Truist Financial cut their target price on shares of IQVIA from $300.00 to $286.00 and set a "buy" rating for the company in a research report on Monday. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, IQVIA has an average rating of "Moderate Buy" and a consensus target price of $267.87.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the firm's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.60% of the stock is currently owned by company insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.